Stocktwits on MSN
CRBP stock surged 36% pre-market – what did its obesity treatment drug study reveal?
CRB-913 is an oral small-molecule inverse agonist targeting the CB1 receptor, a known pathway for weight loss. ・The study ...
Corbus Pharmaceuticals (CRBP) announced the completion of the single ascending dose, or SAD, and multiple ascending dose, or ...
When the Federal Reserve responded to the financial crisis of 2007-08 with hugely unprecedented monetary expansion efforts, many thought that it would lead to runaway inflation and collapse of the U.S ...
CRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for ...
KANSAS CITY, Mo., March 9, 2022 /PRNewswire/ -- CRB, a leading international provider of sustainable engineering, architecture, construction and consulting solutions to the life sciences and food and ...
Corbus Pharmaceuticals announced results from its first-in-human dose escalation study of CRB-701, presented at the ASCO GU 2025 conference. This Phase 1 study assessed the efficacy and safety of ...
Kansas City, Missouri, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CRB, a leading global provider of sustainable engineering, architecture, construction and consulting solutions to the life sciences and food ...
Life sciences veteran Peter Fischer leads CRB's newest Europe office, near Munich. The office in Penzberg is CRB's 21st office overall, and its third in Europe -- joining Stuttgart, Germany, and Basel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback